YHEC offers a range of services to inform the development and conduct of indirect and mixed treatment comparisons (ITC and MTC).
What are Indirect and Mixed Treatment Comparisons?
Indirect and mixed treatment comparisons (network meta-analyses) are new statistical tools for comparing research studies when there is no direct evidence, insufficient direct evidence or more than two interventions need to be compared.
ITC and MTC methods are developing fast. These methods are already widely used in health care to understand better the comparative effectiveness of different treatments, devices and diagnostic techniques.
Working in partnership
Undertaking ITC and MTC requires specialist knowledge. York Health Economics Consortium (leaders in the field of health economics, economic modelling and systematic reviews) and Quantics (leaders in the field of life science statistics) have successfully delivered many ITC and MTC analyses and can provide solutions to your ITC, systematic review, modelling and statistical needs.
To learn more about our services and experience please see the Indirect Treatment Comparisons website.
Examples of Recent Publications
- Malcolm WA, Hodgson R, Glanville J, Barata T, Fleetwood K. Indirect Treatment Comparison of Interventions for Neovascular (Wet) Age-Related Macular Degeneration (Wet AMD). ISPOR 2015.
- Bachelot T, McCool R, Duffy S, Glanville J, Varley D, Fleetwood K, Zhang J, Jerusalem G. Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis. Breast Cancer Res Treat 2014 Jan;143(1):125-33. [Epub ahead of print]
- Bachelot T, Jerusalem G, Cikalo M, McCool R, King S, Duffy S, et al. Comparative efficacy of everolimus versus fulvestrant for hormone-receptor–positive (HR+) advanced breast cancer (ABC) following progression/recurrence after first-line treatment: A network meta-analysis. J Clin Oncol. 2013;31(Suppl):e11602.(Published in conjunction with the 2013 ASCO Annual Meeting).
- Chandiwana D, Vieira J, Bains M, Heaton V, Zhang J, Glanville J, McCool R, Fleetwood K. An indirect treatment comparison of the efficacy of Everolimus (Afinitor®) and Fulvestrant for the treatment of hormone receptor positive (HR+) HER2 negative (HER2-) advanced or metastatic breast cancer. ISPOR Poster 2013.
- Martyn-St.James M, Glanville J, McCool R, Duffy S, Cooper J, Hugel P, Lane P W. The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy a systematic review and indirect comparison. Seizure 2012; 21(9):665-678.